Skip to main content
. 2004 Jan 26;2004(1):CD003133. doi: 10.1002/14651858.CD003133.pub2

1.5. Analysis.

Comparison 1 Leukotriene Receptor Antagonists (LTRA) + ICS vs. same dose of ICS in SYMPTOMATIC patients, Outcome 5 Change from baseline FEV1 using licensed doses of LTRA (at 4 to 16 weeks).